SMS Pharmaceuticals’ (NSE:SMSPHARMA) Earnings Are Of Questionable Quality

Investors were disappointed with SMS Pharmaceuticals Limited’s (NSE:SMSPHARMA) earnings, despite the strong profit numbers. Our analysis uncovered some concerning factors that we believe the market might be paying attention to.

We’ve found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

In order to understand the potential for per share returns, it is essential to consider how much a company is diluting shareholders. In fact, SMS Pharmaceuticals increased the number of shares on issue by 5.6% over the last twelve months by issuing new shares. As a result, its net income is now split between a greater number of shares. Per share metrics like EPS help us understand how much actual shareholders are benefitting from the company’s profits, while the net income level gives us a better view of the company’s absolute size. You can see a chart of SMS Pharmaceuticals’ EPS by clicking here.

How Is Dilution Impacting SMS Pharmaceuticals’ Earnings Per Share (EPS)?

SMS Pharmaceuticals was losing money three years ago. On the bright side, in the last twelve months it grew profit by 48%. On the other hand, earnings per share are only up 43% over the same period. Therefore, the dilution is having a noteworthy influence on shareholder returns.

In the long term, earnings per share growth should beget share price growth. So it will certainly be a positive for shareholders if SMS Pharmaceuticals can grow EPS persistently. However, if its profit increases while its earnings per share stay flat (or even fall) then shareholders might not see much benefit. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company’s share price might grow.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of SMS Pharmaceuticals.

Our Take On SMS Pharmaceuticals’ Profit Performance

Each SMS Pharmaceuticals share now gets a meaningfully smaller slice of its overall profit, due to dilution of existing shareholders. Therefore, it seems possible to us that SMS Pharmaceuticals’ true underlying earnings power is actually less than its statutory profit. But at least holders can take some solace from the 43% EPS growth in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company’s potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it’s worth noting the risks involved. For example, we’ve discovered 1 warning sign that you should run your eye over to get a better picture of SMS Pharmaceuticals.

Today we’ve zoomed in on a single data point to better understand the nature of SMS Pharmaceuticals’ profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to ‘follow the money’ and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.